Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters

Database
Language
Document Type
Year range
1.
Eur Cardiol ; 18: e12, 2023.
Article in English | MEDLINE | ID: covidwho-20241547

ABSTRACT

Cardiac imaging is an ever-evolving area, with imaging parameters and application in constant re-evaluation. This was reflected in many imaging debates and by the increased number of scientific contributions at the European Society of Cardiology Congress in 2022. While clinical trials tried to answer clinical questions related to the performance of different imaging modalities, many high-quality presentations focused on new imaging biomarkers in different scenarios, such as heart failure with preserved ejection fraction, valvular heart disease or long COVID. This highlights the need for the translation of cardiac imaging technology from research interests towards established measures of clinical practice.

2.
Expert Rev Cardiovasc Ther ; 19(1): 5-14, 2021 Jan.
Article in English | MEDLINE | ID: covidwho-894500

ABSTRACT

Introduction: COVID-19 is causing considerable morbidity and mortality worldwide. Serious respiratory complications aside, the heart is also frequently involved. The mechanisms and the extent of the myocardial injury, along with the short and long-term cardiovascular (CV) outcomes in COVID-19 survivors remain unclear. Areas covered: myocardial injury has been found in a considerable proportion of hospitalized COVID-19 patients and is associated with a worse prognosis. The late onset of CV complications with myocarditis-like changes revealed by CMR has been reported in COVID-19 survivors. Previous observational studies on viral myocarditis provide evidence of a significant incomplete recovery with residual dysfunction and remodeling of left ventricle. Incomplete recovery is thought to be the result of persistent myocardial inflammation due to a post-viral autoimmune response. Considering the significant inflammatory nature of COVID-19, COVID-19 survivors may be at risk of developing persistent residual myocardial injury, the sequelae of which are unclear. Expert commentary: COVID-19 is an emerging threat for the heart. The extent of CV injury, along with the short and long-term sequelae, requires further investigation. The early detection of residual myocardial changes in COVID-19 survivors is of utmost importance in order to identify those patients at risk of CV complication development.


Subject(s)
COVID-19/physiopathology , Cardiomyopathies/physiopathology , Heart Failure/physiopathology , Myocarditis/physiopathology , COVID-19/diagnostic imaging , COVID-19/epidemiology , Cardiac Imaging Techniques , Cardiomyopathies/diagnostic imaging , Cardiomyopathies/epidemiology , Early Diagnosis , Heart , Heart Diseases , Heart Failure/diagnostic imaging , Heart Failure/epidemiology , Humans , Inflammation , Magnetic Resonance Imaging , Myocarditis/diagnostic imaging , Myocarditis/epidemiology , Myocardium , Prospective Studies , Recovery of Function , SARS-CoV-2 , Ventricular Remodeling
SELECTION OF CITATIONS
SEARCH DETAIL